Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma

In this study,we evaluated the feasibility,efficacy and toxicity of concurrent chemoradiotherapy with s-1 (tegafur-gimeracil-oteracil potassium) for t2n0 glottic carcinoma. a total of 23 patients with t2n0 glottic carcinoma received chemoradiotherapy with s-1. radiotherapy consisted of five daily fractions of 2 gy per week,to a total median dose of 70 gy. s-1 was administered 65 mg/m2 per day for 4 weeks,beginning on the day therapy was started,followed by 2 weeks off the drug and twice a day until the end of radiotherapy. initial local control rate of the primary tumor was achieved in all patients. the median follow-up period for all patients was 38 months. the 3-year local control rate was 95.4%. regarding adverse reactions,grade 3 mucositis upon clinical examination,mucositis upon functional/symptomatic examination,dysphagia,hepatic toxicity and anemia were observed in 13,2,2,1 and 1 patients,respectively. this chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. chemoradiotherapy with s-1 was feasible,well tolerated and effective. this therapy is suggested as a possible regimen for improving local control of t2n0 glottic carcinoma.